Herein, we aimed to determine the potential clinical usefulness of H3K27me3 immunoexpression in a defined subset of BC patients, more specifically in stage I-III, luminal A/B-like HER2-negative invasive carcinomas, primarily treated with surgery. This evidence concerns the gene ERBB2 and breast cancer.